INLYTA Drug Patent Profile

When do Inlyta patents expire, and when can generic versions of Inlyta launch?

Inlyta is a drug marketed by Pf Prism Cv and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and two patent family members in thirty-one countries.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the axitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Inlyta

Inlyta was eligible for patent challenges on January 27, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 14, 2031. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (axitinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INLYTA

International Patents:	102
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	51
Patent Applications:	4,997
Drug Prices:	Drug price information for INLYTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INLYTA
What excipients (inactive ingredients) are in INLYTA?	INLYTA excipients list
DailyMed Link:	INLYTA at DailyMed

See drug prices for INLYTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INLYTA

Constraining patent/regulatory exclusivity:

8,791,140*PED

NDA:

202324

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INLYTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique Hopitaux De Marseille	PHASE1
Cancer League of Colorado	Phase 2
University of Colorado, Denver	Phase 2

See all INLYTA clinical trials

Pharmacology for INLYTA

Drug Class	Kinase Inhibitor
Mechanism of Action	Receptor Tyrosine Kinase Inhibitors

Paragraph IV (Patent) Challenges for INLYTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INLYTA	Tablets	axitinib	1 mg and 5 mg	202324	1	2018-02-23

US Patents and Regulatory Information for INLYTA

INLYTA is protected by four US patents.

This potential generic entry date is based on patent 8,791,140.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	8,791,140*PED				Y
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	10,869,924*PED				Y
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	10,570,202*PED				Y
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	10,570,202*PED				Y
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	12,534,530*PED				Y

Expired US Patents for INLYTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012	7,141,581
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012	7,141,581

EU/EMA Drug Approvals for INLYTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Inlyta	axitinib	EMEA/H/C/002406Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.	Authorised	no	no	no	2012-09-03

International Patents for INLYTA

When does loss-of-exclusivity occur for INLYTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Finland

Hong Kong

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INLYTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015214390
Brazil	112016017256
Canada	2937521
Canada	3210360
China	105960415

Supplementary Protection Certificates for INLYTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1218348	C300576	Netherlands		PRODUCT NAME: AXITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/12/777/001-006 20120903
1218348	PA2013003	Lithuania		PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903
1218348	CA 2013 00010	Denmark
1218348	92154	Luxembourg		PRODUCT NAME: AXITINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE
1218348	2013/008	Ireland		PRODUCT NAME: AXITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/777/001 EU/1/12/777/006 20120903

Last updated: July 22, 2026

Inlyta (axitinib) Market Dynamics and Financial Trajectory: Sales Drivers, Patent/Generic Outlook, and Revenue Risk (US and EU)

Inlyta (axitinib) is in a mature oncology market where revenue is constrained by post-launch lifecycle effects, competitive TKIs, and US patent/generic entry risk dynamics. Financial trajectory is dominated by (1) uptake in kidney cancer settings (RCC) across line-of-therapy and combination regimens, (2) payor and guideline shifts toward newer combinations and next-generation VEGFR/PD-1 strategies, and (3) exclusivity and patent estate durability that delays generic substitution in the core US market. In practice, the revenue curve has moved from rapid adoption post-launch to slower growth and then mid-single-digit to low-growth depending on line-of-therapy penetration, channel mix, and pricing actions.

---

How has Inlyta (axitinib) performed financially over time?

Direct answer: Inlyta’s financial trajectory is typical of branded oncology oral TKIs: peak and then deceleration as competitive regimens broaden and pricing pressure increases, with incremental resilience from label expansions, combination strategies, and sequence-based prescribing in advanced RCC.

Key portfolio context

• Molecule: axitinib
• Brand: Inlyta
• Company (brand owner historically): Pfizer
• Clinical positioning: advanced renal cell carcinoma (RCC), with multiple regimen and line-of-therapy touchpoints across treatment-naïve and post–immunotherapy settings.

What drives the revenue curve in mature TKIs

• Regimen mix: share shifting among monotherapy vs combinations (notably PD-1 based combinations) and among first-line vs subsequent-line usage.
• Net price and rebates: mature portfolio dynamics where discounting is used to retain formulary access.
• Real-world duration: adherence and discontinuation vary by toxicity profile (hypertension, diarrhea, fatigue), influencing dose intensity and persistence.
• Guideline evolution: RCC practice has shifted toward combinations and, more recently, toward regimens that incorporate newer agents and dosing strategies.

Financial read-through (what investors underwrite)

• Revenue in mature branded oncology is less about new prescriber adoption and more about:
  • maintaining formulary placement,
  • reducing competitive churn from other VEGFR TKIs and combination competitors,
  • sustaining dose and adherence through supportive care protocols, and
  • timing of generic substitution risk.

---

What market dynamics shape Inlyta revenue in advanced renal cell carcinoma?

Direct answer: Inlyta revenue is driven by VEGF-pathway demand in RCC plus combination oncology adoption, offset by the rise of competing multi-agent regimens and the pricing pressure that comes with an aging label footprint.

1) Competitive landscape: where Inlyta wins and where it loses

In mature RCC, clinicians choose among:

• VEGFR TKIs (including other agents with similar targets or comparable toxicity management),
• immunotherapy combinations (PD-1/L1 + VEGF-axis strategies),
• subsequent-line alternatives after prior immunotherapy exposure.

Market dynamic effects

• Formulary steering: national and regional payors prefer regimens with favorable outcomes per cost and low budget impact.
• Sequence: if Inlyta is used later in therapy, total addressable population can narrow as first-line regimens dominate patient flow.
• Switching: patients frequently switch TKIs after intolerance or progression, but switching also increases erosion risk if another branded competitor retains better persistence or has more favorable subgroup evidence.

2) Payor and guideline pressures

• RCC guidelines and evidence updates influence:
  • treatment sequencing,
  • combination selection,
  • and preference for specific VEGFR partners.
• As regimens age, payors negotiate harder and clinicians face more payer-driven prior authorization requirements.

3) Safety and access

• Oral oncolytics have practical adoption barriers: dose adjustments for adverse events, blood pressure management, and patient support programs.
• Improved supportive care can protect persistence and reduce effective churn, stabilizing revenue.

---

What is the Orange Book and exclusivity status of Inlyta (axitinib) in the US?

Direct answer: Inlyta’s continued branded sales depend on patent coverage and regulatory exclusivity that can delay ANDA approvals and/or limit launch timing for generic axitinib products.

Orange Book status mechanics that matter commercially

For an oral small molecule oncology drug, exclusivity typically hinges on:

• patent expiration for listed NDA patents (composition, formulation, method-of-use, and related claims),
• exclusivity periods (if any, separate from patents, such as new chemical entity exclusivity when applicable), and
• availability of Paragraph IV opportunities tied to specific listed patents.

Commercial implication: Even if a branded drug is mature, generics often wait for a clear patent carve-out to avoid infringement risk and to ensure sufficient exclusivity-free launch timing.

---

When does Inlyta lose exclusivity in the US, and what are the generic entry risks?

Direct answer: Generic substitution risk is a function of the earliest expiration among relevant Orange Book-listed patents and the strength and enforceability of the remaining estate. For mature TKIs, the “first meaningful risk date” is the earliest date when a challenger can reasonably reach a non-infringing launch and still maintain an FDA-approved ANDA.

Generic entry risk framework for investors

• Earliest patent expiry: sets the outer boundary for a challenger launch.
• Patent clustering: multiple claims across composition, method-of-use, and formulation can extend effective launch timing even after one patent expires.
• Litigation outcomes: settlements can “pay-to-delay” in practice, typically expressed via agreed entry dates or stipulations that constrain early launching.

Practical takeaway: A branded oncology product can retain revenue for years after initial perception of “patent expiry,” if litigation, injunction risk, or settlement-entry-date terms extend the effective exclusivity window.

---

How strong is the patent estate for Inlyta (axitinib) versus other VEGFR TKIs?

Direct answer: In mature branded oncology, patent strength is less about a single blockbuster patent and more about claim breadth across:

• composition of matter,
• polymorphs/solid forms (if applicable),
• formulations (including dose forms and excipients),
• manufacturing or process methods (where available),
• and method-of-use claims tied to RCC treatment regimens.

How to judge enforceability for a small-molecule TKI

• Composition claims tend to be durable but may be narrower depending on actual claim scope.
• Method-of-use claims are vulnerable when clinical practice no longer maps to the claim language or when label scope changes.
• Formulation/process claims often sustain market protection even after therapeutic method claims narrow, but strength depends on how many ANDA technologies can plausibly “design around.”

---

What formulations and dosing regimens are protected for Inlyta?

Direct answer: For oral small molecules like axitinib, the most commercially relevant IP usually includes formulation-related claims covering specific dosage forms and solid-state/processing attributes, plus method-of-use claims that are tied to RCC regimens.

Commercially relevant claim types

• Dose form coverage: tablets/capsules and administration characteristics.
• Stability/solubility enhancements: if claimed, these can limit generic “bioequivalent” workarounds.
• Method-of-use coverage: regimens by line of therapy or combination pairing.

Market effect: If formulation and process patents remain in-force, generic launch delays even when method-of-use coverage weakens.

---

How has Inlyta been positioned in combination regimens, and how does that affect sales durability?

Direct answer: Combination placement supports sales durability by embedding axitinib into specific clinical pathways. Sales resilience increases when clinicians treat axitinib as a backbone partner in PD-1/L1 or immunotherapy combinations across broader patient populations.

Combination-driven demand

• Combination regimens typically expand:
  • eligible patient count,
  • time on therapy,
  • and line-of-therapy persistence.
• Combination anchoring also increases switching costs, since later-line re-treatment may still rely on a VEGFR-axis strategy.

Where combination anchoring breaks

• Rapid guideline shifts toward alternative VEGFR partners can reduce the incremental population.
• If a competitor demonstrates superior outcomes in a specific subgroup, payors can steer using outcomes-per-cost thresholds.

---

Which companies are challenging Inlyta, and what does that imply for timing?

Direct answer: Generic challenges usually express themselves through ANDA Paragraph IV filings tied to specific Orange Book patents. The commercial implication is straightforward: each challenge increases the probability of earlier launch dates, but settlement and injunction outcomes can still push effective entry later.

What to track

• Paragraph IV notice dates: signal probability of near-term generic readiness.
• Litigation timelines: filing-to-hearing cadence affects launch predictability.
• Settlement terms: entry dates, licensing conditions, and product shelf arrangement.

Market consequence: Generic risk is not only “if” but “when” based on settlement-entry date mechanics.

---

What Inlyta patent litigation and settlements affect generic launch schedules?

Direct answer: Generic launch schedules for branded oral oncology drugs are heavily influenced by settlement agreements that define launch dates and scope-of-product constraints.

Litigation milestones investors track

• complaint and answer filing dates,
• claim construction outcomes,
• injunction rulings,
• appellate decisions,
• settlement entry dates.

Revenue impact: Even after a generic is ready, branded revenue can be sustained by negotiated launch timing and “skinny label” or carve-out constraints that reduce or delay practical substitution.

---

What is the biosimilar or biologics relevance of Inlyta?

Direct answer: Inlyta is a small-molecule drug and does not have biosimilar competition mechanics. Its competitive threats are ANDA generics and potential authorized generics, not biologic biosimilars.

Commercial implication: the primary substitution pathway is chemical generic equivalence under ANDA, not biosimilar interchangeability.

---

How does Inlyta compare with rival VEGFR TKIs on market traction?

Direct answer: Axitinib’s market traction historically benefited from strong RCC efficacy data and integration into PD-1-based combinations. Revenue erosion tends to follow when competitor TKIs secure:

• stronger payer preference,
• better persistence/dose intensity in real-world practice, or
• better clinical positioning in specific subgroups and treatment lines.

Comparative market drivers to benchmark

• Line of therapy: first-line volume typically grows total demand; later-line volume limits growth.
• Combination share: PD-1 partner selection affects prescription inertia.
• Toxicity management: real-world persistence impacts effective utilization, not just initial prescribing.

---

What revenue exposure does generic entry create for Inlyta?

Direct answer: Revenue exposure is high once generic entry occurs at meaningful market share scale because oral oncology TKIs face rapid price erosion after ANDA launch. The magnitude depends on:

• number of generic entrants,
• speed of payer switching,
• formulary behavior,
• and settlement constraints that delay substitution.

High-level exposure model

• Pre-launch: revenue largely stable unless prices are cut pre-emptively.
• At-launch: steep decline is common if multiple ANDAs launch and payors adopt automatic therapeutic interchange.
• Post-launch: brand may persist as a higher net price product through specialty channel inertia, patient support programs, and brand preference, but the center of gravity shifts to lowest net cost.

---

Key Takeaways

• Inlyta’s financial trajectory reflects mature oncology dynamics: combination-driven durability offset by competition, payor pressure, and regimen sequencing changes.
• Commercial risk concentrates around US patent and Orange Book timing, where earlier expiry alone does not guarantee generic entry if litigation and settlements extend launch dates.
• The strongest revenue sustainers are label-relevant combination regimens and formulation/method-of-use IP breadth that blocks design-around and delays ANDA approvals.
• The principal substitution threat is ANDA generic entry, not biosimilars.

---

FAQs

1) What are the main US patent and FDA-regulatory levers that govern Inlyta generic timing?
Earliest Orange Book patent expiry across relevant NDA-listed patents, Paragraph IV challenge outcomes, and settlement or injunction effects on effective launch dates.

2) Does Inlyta’s combination positioning increase long-term sales or accelerate competitive substitution?
It increases patient volume and treatment-path anchoring, but competitive shifts in PD-1/VEGF regimen preferences can still accelerate share loss.

3) How do payors typically respond to branded axitinib in a mature RCC portfolio?
They negotiate net price, impose prior authorization, and steer toward lower net-cost regimens where comparative evidence and budget impact support substitution.

4) What types of IP are most protective for an oral oncology TKI like Inlyta?
Composition, formulation/solid-state or manufacturing/process claims where present, and method-of-use claims tied to specific RCC regimens.

5) What does a settlement in Inlyta patent litigation usually change for market access?
It defines a practical entry date and constrains launch scope, reducing uncertainty and often preserving branded revenue until the agreed date.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (US FDA).
2. Pfizer. Inlyta (axitinib) Prescribing Information. (Accessed via FDA label repository).
3. FDA. Drug Approval Reports and NDA information for Inlyta (axitinib). (US FDA).

DrugChatter Q&A for INLYTA

Inlyta loss of exclusivity uk?
Inlyta lose of exclusivity?
Inlyta lose of exclusivity china?
Can inlyta be used with bavencio?
Is inlyta used in combination with keytruda?